Results for this period
Full year1 April 2025–31 March 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
In the pharmaceutical wholesale business, revenue increased due to a focus on sales of products eligible for the premium for new drug creation and seasonal products, but profit declined because of the NHI drug price revision, lower sales resulting from competitive bidding, and higher selling, general and administrative expenses amid rising prices. The pharmacy business reported higher revenue and a slight increase in profit due to increased dispensing technical fee revenue and pharmaceutical management fee revenue, together with cost controls. The veterinary pharmaceutical wholesale business reported higher revenue following the consolidation of アローメディカル, but profit declined as it was unable to absorb the increase in costs. The pharmaceutical business recorded a loss after recognizing ¥1,312 million in research and development expenses and other costs. The nursing care rental and other businesses reported higher revenue following the consolidation of subsidiaries, but the loss widened due to higher personnel and fuel costs. On a company-wide basis, the Company recorded ¥2,742 million in gains on investment in investment partnerships and ¥4,080 million in gains on sales of investment securities.
None ("There are no applicable matters.")
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥610,497 million (YoY +1.7%) |
| Operating profit | ¥4,027 million (YoY -29.4%) |
| Ordinary income | ¥7,822 million (YoY +12.2%) |
| Profit attributable to owners of the parent | ¥7,362 million (YoY +0.7%) |
| Net income per share | ¥152.29 |
| Operating Margin | 0.7% |
| Equity ratio | End of the current fiscal period 36.6% / End of previous period 35.4% |
| Total assets | ¥320,568 million |
| Net assets | ¥118,707 million |
| Cash flows from operating activities | ¥4,833 million |
| Cash flows from investing activities | ¥-1,071 million |
| Cash flows from financing activities | ¥-4,399 million |
| Cash and cash equivalents at end of period | ¥19,437 million |
| Full-year earnings forecast | Net Sales ¥620,000 million (YoY +1.6%) / Operating profit ¥4,100 million (YoY +1.8%) / Ordinary income ¥5,000 million (YoY -36.1%) / Profit attributable to owners of the parent ¥7,500 million (YoY +1.9%) |
| Annual Dividend Forecast | ¥45 per share → ¥70 per share（+55.6%） |
| Payout ratio | 46.0% |
| Shareholder Return Policy | DOE of at least 3%, dividend payout ratio of approximately 40–45%, no total payout ratio policy, and flexible share repurchases |
| Segment revenue | Pharmaceutical wholesale business ¥572,860 million (YoY +1.5%), Pharmacy business ¥19,960 million (YoY +2.1%), Veterinary pharmaceutical wholesale business ¥12,627 million (YoY +8.6%), Pharmaceutical business (support for the introduction of unapproved drugs) －, Nursing care rental and other businesses ¥5,048 million (YoY +10.3%) |
| Segment profit | Pharmaceutical wholesale business ¥4,920 million (YoY -4.7%), Pharmacy business ¥252 million (YoY +0.3%), Veterinary pharmaceutical wholesale business ¥304 million (YoY -3.0%), Pharmaceutical business (support for the introduction of unapproved drugs) ¥-1,312 million, Nursing care rental and other businesses ¥-102 million |
| Depreciation and amortization | ¥3,852 million |
| Impairment loss | ¥194 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥81 million, Gain on sale of investment securities ¥4,080 million, Other ¥56 million / Extraordinary loss Loss on sale of fixed assets ¥19 million, Impairment Losses ¥194 million, Impairment loss on investment securities ¥129 million, Impairment Losses on Shares of Affiliates ¥168 million, Other ¥27 million |
| Disclosure regarding the going concern assumption | None ("There are no applicable matters.") |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | No significant changes were reported on the cover page. The main text states that the Company established メドリープファーマ and made 共和運送, 八千代ケアホールディングス and アローメディカル subsidiaries. It also states that 八千代ケアサポート was added. The number and names of excluded companies are not disclosed. |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Available (for institutional investors and analysts) |
| Issued Shares at Period-End | 51,902,976 |
| Treasury Shares at Period-End | 3,525,894 |
| Factors Behind Changes in Business Performance | In the pharmaceutical wholesale business, revenue increased due to a focus on sales of products eligible for the premium for new drug creation and seasonal products, but profit declined because of the NHI drug price revision, lower sales resulting from competitive bidding, and higher selling, general and administrative expenses amid rising prices. The pharmacy business reported higher revenue and a slight increase in profit due to increased dispensing technical fee revenue and pharmaceutical management fee revenue, together with cost controls. The veterinary pharmaceutical wholesale business reported higher revenue following the consolidation of アローメディカル, but profit declined as it was unable to absorb the increase in costs. The pharmaceutical business recorded a loss after recognizing ¥1,312 million in research and development expenses and other costs. The nursing care rental and other businesses reported higher revenue following the consolidation of subsidiaries, but the loss widened due to higher personnel and fuel costs. On a company-wide basis, the Company recorded ¥2,742 million in gains on investment in investment partnerships and ¥4,080 million in gains on sales of investment securities. |
Items this document does not state (3)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the pharmaceutical wholesale business, lower sales resulting from the NHI drug price revision and competitive bidding, together with higher selling, general and administrative expenses amid rising prices, put downward pressure on operating profit. On the other hand, the Company recorded ¥2,742 million in gains on investment and other income associated with the sale of CareNet shares as non-operating income, and ¥4,080 million in gains on sales of investment securities, including sales of cross-shareholdings, as extraordinary income.